BEAM as reported
Beam Therapeutics Inc. reported $156M of revenue over the trailing twelve months, +159% on the year before. 8 reported series are charted on this page, each one as filed.
$156M
Revenue, trailing twelve months · to Q2 2026 · +159% against the twelve months before
- Net Income
- −$85M
Net Income · −79% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$373M
Free Cash Flow · +4.8% year on year · trailing twelve months to Q2 2026
- Op Margin
- −6872%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $156M | +159% | Q2 2026 |
| Net Income | −$85M | −79% | Q2 2026 |
| EPS | −$0.68 | −85% | Q2 2026 |
| Op Margin | −6872% | n/a | Q2 2026 |
| Net Margin | −6570% | n/a | Q2 2026 |
| ROE | −16% | n/a | Q2 2026 |
| ROA | −12% | n/a | Q2 2026 |
| Free Cash Flow | −$373M | +4.8% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Beam Therapeutics Inc. (BEAM) - Revenue & ProfitRevenue & ProfitBeam Therapeutics Inc. (BEAM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com